Stopping Aspirin Before Surgery
For patients on low-dose aspirin (81 mg) for secondary cardiovascular prevention, aspirin should generally be continued throughout the perioperative period for most elective surgeries; however, for primary prevention, aspirin should be discontinued 3-5 days before surgery. 1
Decision Framework Based on Indication
Secondary Prevention (Established Cardiovascular Disease)
Continue aspirin perioperatively for patients with:
- History of myocardial infarction
- Prior stroke or TIA
- Coronary artery disease
- Peripheral arterial disease
- Coronary stents (especially critical)
The rationale is straightforward: the cardiovascular risk of aspirin withdrawal substantially outweighs bleeding risk for most procedures 2, 1. Evidence demonstrates that aspirin withdrawal can precipitate acute cardiovascular events, with timing averaging 8.5 days for acute coronary syndromes and 14.3 days for cerebral events after discontinuation 3.
Primary Prevention (No Established Cardiovascular Disease)
Discontinue aspirin 3-5 days before surgery 4, 5. Recent evidence shows minimal benefit and increased bleeding risk for primary prevention patients perioperatively 6. The 2022 USPSTF guidelines have significantly restricted aspirin use for primary prevention, making perioperative continuation even less justified 7, 6.
High-Risk Bleeding Procedures Requiring Aspirin Cessation
Even for secondary prevention patients, stop aspirin 5 days before these specific procedures 2, 8:
- Intracranial neurosurgery
- Intramedullary spinal surgery
- Posterior eye chamber surgery
- Middle ear surgery
- Possibly transurethral prostatectomy
The 5-day window allows for adequate platelet function recovery, as studies demonstrate normalization of bleeding times within 96 hours and complete platelet function recovery within 144 hours 9.
Special Consideration: Patients with Coronary Stents
This represents the highest-risk scenario for aspirin withdrawal:
Never stop aspirin in patients with:
- Drug-eluting stent (DES) placed within 12 months 10, 11, 1
- Bare-metal stent (BMS) placed within 30 days 1
If dual antiplatelet therapy (DAPT) must be interrupted for urgent surgery:
- Continue aspirin at all costs 12, 2, 1
- Stop P2Y12 inhibitor (clopidogrel/ticagrelor) 5 days before surgery 10, 11
- Stop prasugrel 7 days before surgery 10, 11
- Resume P2Y12 inhibitor within 24 hours postoperatively 12
The risk of catastrophic stent thrombosis (resulting in MI or death in the majority of cases) far exceeds surgical bleeding risk 2.
Practical Implementation Algorithm
Step 1: Identify aspirin indication
- Secondary prevention → Proceed to Step 2
- Primary prevention → Stop 3-5 days preoperatively
Step 2: Assess procedure bleeding risk
- Closed-space surgery (intracranial, intramedullary spine, posterior eye, middle ear) → Stop 5 days preoperatively
- All other surgeries → Continue aspirin
Step 3: Check for coronary stents
- DES <12 months or BMS <30 days → Never stop aspirin, delay elective surgery if possible 1
- If surgery cannot be delayed → Continue aspirin, multidisciplinary consultation required 13
Step 4: Postoperative management
- Resume aspirin within 24 hours if held 5
- For stent patients, resume P2Y12 inhibitor as soon as hemostasis achieved, ideally within 24 hours 12
Common Pitfalls to Avoid
Do not confuse aspirin dose with indication: The 81 mg dose is appropriate for both primary and secondary prevention 14, 15. Higher doses (325 mg) offer no additional cardiovascular benefit and increase bleeding risk 14.
Do not use bridging therapy: Unlike anticoagulation management, there is no role for heparin or other bridging when holding aspirin 4.
Do not assume all cardiovascular patients are the same: Recent stroke patients have particularly high thrombotic risk; neurological consultation is essential if considering aspirin cessation 13.
Do not restart aspirin too late: The prothrombotic rebound effect begins immediately after cessation 8. If aspirin was held, restart within 24 hours postoperatively unless ongoing bleeding 5.
Evidence Quality Note
The strongest guideline evidence comes from the 2014 ACC/AHA guidelines 1 and 2022 ACCP perioperative management guidelines 5, both emphasizing continuation for secondary prevention. The shift away from routine primary prevention use is supported by recent USPSTF guidelines 6 and multiple large trials showing no net benefit for primary prevention in the perioperative setting 16, 6.
For CABG specifically, aspirin continuation is a Class I recommendation with Level B evidence, demonstrating reduced perioperative MI without increased mortality risk from bleeding 11, 15.